PLEASANTON, Calif. , Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc.
(Nasdaq: TXG ), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024 . Preliminary Select Third Quarter 2024 Results Revenue of approximately $151.7 million for the third quarter ended September 30, 2024 , representing an approximate 1% decrease from the corresponding prior year period.
Preliminary revenue by source for the third quarter is expected to be as follows: Instruments revenue of approximately $19.1 million , representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.
6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue. Consumables revenue of approximately $126.
2 million , representing 10% growth over the corresponding prior year period. Consumables revenue consists of approximately $96.5 million of Chromium consumables revenue and $29.
7 million of Spatial consumables revenue. Services revenue of approximately $6.4 million , representing 48% growth over the corresponding prior year period.
Preliminary revenue by geography for the third quarter is expected to be as follows: Americas revenue of approximately $87.8 million , an 11% decrease from the prior year period. EMEA revenue of approximately $37.
9 million , an 18% increase over the prior year period. APAC revenue of approximately $26.0 million , a 15% increase over the.
